Effect of tiplaxtinin (PAI‐039), an orally bioavailable PAI‐1 antagonist, in a rat model of thrombosis

No abstract is available for this paper.

• Publication year

  2008

• Venue

  Journal of Thrombosis and Haemostasis

• Publication date

  2008-09-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1111/j.1538-7836.2008.03063.xPMID 18624980
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Mechanism of Inactivation of Plasminogen Activator Inhibitor-1 by a Small Molecule Inhibitor*

  2007cited by this paper
• Effect of pharmacologic plasminogen activator inhibitor‐1 inhibition on cell motility and tumor angiogenesis

  2006cited by this paper
• Thrombotic phenotype of mice with a combined deficiency in plasminogen activator inhibitor 1 and vitronectin

  2005cited by this paper
• Evaluation of PAI-039 [{1-Benzyl-5-[4-(trifluoromethoxy)phenyl]-1H-indol-3-yl}(oxo)acetic Acid], a Novel Plasminogen Activator Inhibitor-1 Inhibitor, in a Canine Model of Coronary Artery Thrombosis

  2005cited by this paper
• Tiplaxtinin, a novel, orally efficacious inhibitor of plasminogen activator inhibitor-1: design, synthesis, and preclinical characterization.

  2004cited by this paper
• Basic and Clinical Aspects of Fibrinolysis and Thrombolysis

  2003cited by this paper
• Plasminogen activator inhibitor-1 in tumor growth, angiogenesis and vascular remodeling.

  2003cited by this paper
• Plasminogen Activator Inhibitor-1 and Its Cofactor Vitronectin Stabilize Arterial Thrombi After Vascular Injury in Mice

  2001cited by this paper
• Plasminogen activator inhibitor-1 deficiency protects against atherosclerosis progression in the mouse carotid artery.

  2000cited by this paper
• Plasminogen activator inhibitor-1 is a major determinant of arterial thrombolysis resistance.

  1999cited by this paper
• The Fab-fragment of a PAI-1 Inhibiting Antibody Reduces Thrombus Size and Restores Blood Flow in a Rat Model of Arterial Thrombosis

  1997cited by this paper
• Evaluation of a Low Molecular Weight Modulator of Human Plasminogen Activator Inhibitor-1 Activity

  1996cited by this paper
• Two functionally distinct pools of vitronectin (Vn) in the blood circulation: identification of a heparin-binding competent population of Vn within platelet alpha-granules.

  1996cited by this paper
• Thrombolysis and reocclusion in experimental jugular vein and coronary artery thrombosis. Effects of a plasminogen activator inhibitor type 1-neutralizing monoclonal antibody.

  1995cited by this paper
• Plasminogen activator inhibitor-1 released from activated platelets plays a key role in thrombolysis resistance. Studies with thrombi generated in the Chandler loop.

  1994cited by this paper
• Lewis A. Conner Memorial Lecture. Mechanisms leading to myocardial infarction: insights from studies of vascular biology.

  1994cited by this paper
• Localization of tissue plasminogen activator in the endothelium of a limited number of vessels.

  1994cited by this paper
• Inhibition of Plasminogen Activator Inhibitor‐1 Activity Results in Promotion of Endogenous Thrombolysis and Inhibition of Thrombus Extension in Models of Experimental Thrombosis

  1992cited by this paper
• Plasminogen activator inhibitor-1 binds to fibrin and inhibits tissue-type plasminogen activator-mediated fibrin dissolution.

  1992cited by this paper
• Basic and clinical aspects of fibrinolysis and thrombolysis.

  1991cited by this paper
• Rat model of arterial thrombosis induced by ferric chloride.

  1990cited by this paper
• Identification of and partial characterization of platelet vitronectin: evidence for complex formation with platelet-derived plasminogen activator inhibitor-1.

  1989cited by this paper
• Detection and partial characterization of an inhibitor of plasminogen activator in human platelets.

  1984cited by this paper

• Physiopathology of fibrinolysis in sepsis-induced disseminated intravascular coagulation: Emerging mechanisms and pharmacological targets.

  2026cites this paper
• Tissue plasminogen activator modified thromboelastography identifies fibrinolysis resistance in dogs with immune-mediated hemolytic anemia

  2025cites this paper
• Beyond Direct Fibrinolysis: Novel Approaches to Thrombolysis

  2025cites this paper
• The fibrinolytic system in disease: From molecular pathways to clinical outcomes.

  2025cites this paper
• Clot formation, structure, and fibrinolysis of pancreatic cancer patients

  2025cites this paper
• Clot formation, structure, and fibrinolysis of plasma from pancreatic cancer patients

  2025cites this paper
• Targeting Fibrinolytic Inhibition for Venous Thromboembolism Treatment: Overview of an Emerging Therapeutic Approach.

  2024cites this paper
• Regulation of macrophage fibrinolysis during venous thrombus resolution.

  2024cites this paper
• Time-dependent ultrastructural changes during venous thrombogenesis and thrombus resolution.

  2024cites this paper
• Obesity paradox in acute myocardial infarction: is plasminogen activator inhibitor 1 the culprit?

  2023cites this paper
• The Fibrinolytic System and Its Measurement: History, Current Uses and Future Directions for Diagnosis and Treatment

  2023cites this paper
• Thrombosis Models: An Overview of Common In Vivo and In Vitro Models of Thrombosis

  2023cites this paper
• Adipokines from white adipose tissue in regulation of whole body energy homeostasis.

  2022cites this paper
• Compartmentalized Actions of the Plasminogen Activator Inhibitors, PAI-1 and Nsp, in Ischemic Stroke

  2022cites this paper
• Fibrinolysis in Venous Thromboembolism

  2021cites this paper
• Development of potent and selective inhibitors targeting the papain-like protease of SARS-CoV-2

  2021cites this paper
• Fibrin Network Formation and Lysis in Septic Shock Patients

  2021cites this paper
• Cancer-associated fibroblast-induced M2-polarized macrophages promote hepatocellular carcinoma progression via the plasminogen activator inhibitor-1 pathway

  2021cites this paper
• Inhibition of plasminogen activator inhibitor-1 blocks programmed death ligand 1 endocytosis and improves the response of melanoma cells to immune checkpoint blockade.

  2021cites this paper
• Structural Insight into the Two-Step Mechanism of PAI-1 Inhibition by Small Molecule TM5484

  2021cites this paper
• Plasminogen Activator Inhibitor-1 Secretion by Autophagy Contributes to Melanoma Resistance to Chemotherapy through Tumor Microenvironment Modulation

  2021cites this paper
• Fibrinolytic Alterations in Sepsis: Biomarkers and Future Treatment Targets

  2021cites this paper
• tPA Deficiency Underlies Neurovascular Coupling Dysfunction by Amyloid-β

  2020influential citation
• Embelin ameliorated sepsis-induced disseminated intravascular coagulation intensities by simultaneously suppressing inflammation and thrombosis.

  2020cites this paper
• Therapeutics targeting the fibrinolytic system

  2020cites this paper
• Timing of Heparin Administration Modulates Arterial Occlusive Thrombotic Response in Rats

  2020cites this paper
• Fibrinolysis and Inflammation in Venous Thrombus Resolution

  2019cites this paper
• Molecular biomarkers of Graves' ophthalmopathy.

  2019cites this paper
• Role of plasminogen activator inhibitor-1 in coronary pathophysiology.

  2018cites this paper
• A long-acting PAI-1 inhibitor reduces thrombus formation

  2017cites this paper
• Inhibition of PAI-1 Activity by Toddalolactone as a Mechanism for Promoting Blood Circulation and Removing Stasis by Chinese Herb Zanthoxylum nitidum var. tomentosum

  2017cites this paper
• Bioactivity-Guided Fractionation of the Traditional Chinese Medicine Resina Draconis Reveals Loureirin B as a PAI-1 Inhibitor

  2017cites this paper
• Identification Of Lipolysis-Derived Lipid Mediators And The Activation Of A Pro-Inflammatory Cyclooxygenase Pathway, Via Cyclooxygenase-2, In Adipose Tissue

  2016cites this paper
• Characterization of the Annonaceous acetogenin, annonacinone, a natural product inhibitor of plasminogen activator inhibitor-1

  2016cites this paper
• Modulation of plasminogen activator inhibitor-1 (PAI-1) by the naphthoquinone shikonin.

  2016cites this paper
• Novel anti-thrombotic agent for modulation of protein disulfide isomerase family member ERp57 for prophylactic therapy

  2015cites this paper
• Plasminogen Activator Inhibitor-1 in Cancer: Rationale and Insight for Future Therapeutic Testing.

  2015cites this paper
• Plasminogen Activator Inhibitor-1 Controls Vascular Integrity by Regulating VE-Cadherin Trafficking

  2015cites this paper
• Evaluation of Antithrombotic Activity of Thrombin DNA Aptamers by a Murine Thrombosis Model

  2014cites this paper
• Adipose Tissue and Adipokines: The Association with and Application of Adipokines in Obesity

  2014cites this paper
• Chemical Antagonists of Plasminogen Activator Inhibitor-1: Mechanisms of Action and Therapeutic Potential in Vascular Disease

  2014cites this paper
• Enhanced venous thrombus resolution in plasminogen activator inhibitor type‐2 deficient mice

  2014cites this paper
• Inhibition of PAI-1 Antiproteolytic Activity Against tPA by RNA Aptamers

  2014cites this paper
• Characterisation, development and application of a clinical model of thrombosis and fibrinolysis

  2014cites this paper
• TM5275 prolongs secreted tissue plasminogen activator retention and enhances fibrinolysis on vascular endothelial cells.

  2013cites this paper
• The Apparent uPA/PAI-1 Paradox in Cancer: More than Meets the Eye

  2013cites this paper
• Plasminogen activator inhibitor-1 levels and activity decrease after intervention in patients with critical limb ischaemia.

  2013cites this paper
• Plasminogen activator inhibitor-1 inhibitors: a patent review (2006 – present)

  2013cites this paper
• A plasminogen activator inhibitor-1 inhibitor reduces airway remodeling in a murine model of chronic asthma.

  2012cites this paper
• Plasminogen Activator Inhibitor-1 and Thrombotic Cerebrovascular Diseases

  2012cites this paper
• Maximal PAI-1 inhibition in vivo requires neutralizing antibodies that recognize and inhibit glycosylated PAI-1.

  2012cites this paper
• Protumorigenic activity of plasminogen activator inhibitor-1 through an antiapoptotic function.

  2012cites this paper
• [Prevention and treatment of hepatic veno-occlusive disease].

  2011cites this paper
• An optimized method to assess in vivo efficacy of antithrombotic drugs using optical coherence tomography and a modified Doppler flow system.

  2011cites this paper
• Optimization of Ferric Chloride Induced Carotid Artery Thrombosis Model in a Rat: Effect of Ginkgo biloba Extracts

  2011cites this paper
• Development of inhibitors of plasminogen activator inhibitor-1.

  2011cites this paper
• Evaluation of anti-platelet and anti-thrombotic effects of cilostazol with PFA-100® and Multiplate® whole blood aggregometer in vitro, ex vivo and FeCl3-induced thrombosis models in vivo.

  2011cites this paper
• Effect of the small molecule plasminogen activator inhibitor‐1 (PAI‐1) inhibitor, PAI‐749, in clinical models of fibrinolysis

  2010cites this paper
• Plasminogen activator inhibitor 1: mechanisms of its synergistic regulation by growth factors

  2010cites this paper
• Review: Therapeutic potential of plasminogen activator inhibitor-1 inhibitors

  2010cites this paper
• Effects of pharmacological inhibition and genetic deficiency of plasminogen activator inhibitor-1 in radiation-induced intestinal injury.

  2009cites this paper
• Species-dependent molecular drug targets in plasminogen activator inhibitor-1 (PAI-1)

  2009cites this paper